Results for orathecin translation from English to Slovenian

what is orathecin?
kaj je zdravilo orathecin?

how is orathecin expected to work?
kako naj bi zdravilo orathecin delovalo?

what was orathecin expected to be used for?
za kaj naj bi se zdravilo orathecin uporabljalo?

orathecin is a capsule to be taken orally.
zdravilo orathecin so kapsule, ki se jemljejo peroralno.

orathecin has been investigated in two main clinical studies.
zdravilo orathecin so preizkusili v dveh glavnih kliničnih raziskavah.

orathecin belongs to a group of alkaloids called camptothecins.
zdravilo orathecin spada v skupino alkaloidov, ki jim pravimo kamptotecini.

questions and answers on withdrawal of marketing application for orathecin
vpraŠanja in odgovori glede umika vloge za dovoljenje za promet za zdravilo orathecin

orathecin was designated as an orphan medicinal product on 10 june 2003.
zdravilo orathecin je bilo 10. junija 2003 določeno kot zdravilo sirota.

orathecin contains 0.5 or 1.25 of the active substance rubitecan.
zdravilo orathecin vsebuje 0, 5 mg ali 1, 25 mg zdravilne učinkovine rubitekan.

by blocking this protein, orathecin is expected to damage the cancer cells.
z blokiranjem te beljakovine naj bi zdravilo orathecin poškodovalo rakave celice.

moreover, patients treated with orathecin experienced many side effects, including serious ones.
razen tega so imeli bolniki, ki so bili zdravljeni z zdravilom orathecin, veliko neželenih učinkov, vključno z resnimi neželenimi učinki.

the effects of orathecin were first tested in experimental models before being studied in humans.
učinki zdravila orathecin so bili najprej preizkušeni s pomočjo izkustvenih modelov, nato pa so jih raziskali pri ljudeh.

orathecin was given to the patients until their cancer progressed or they could not tolerate the treatment anymore.
Čas preživetja teh bolnikov so primerjali s časom preživetja bolnikov, ki so prejemali zdravila, ki se običajno uporabljajo za zdravljenje raka trebušne slinavke, med drugim 5- fluorouracil (5- fu) ali gemcitabin.

what are the consequences of the withdrawal for patients undergoing clinical trials / compassionate use programmes with orathecin?
kakšne so posledice umika za bolnike, ki sodelujejo v kliničnih preizkušanjih / programih sočutne uporabe z zdravilom orathecin?

in the studies presented by the company, it could not be shown that orathecin extends the life of patients nor improves their quality of life.
raziskave, ki jih je predložilo podjetje, niso pokazale, da zdravilo orathecin podaljša življenje bolnikov ali izboljša kakovost njihovega življenja.

based on the review of the data and the company’ s response to the chmp list of questions, at the time the withdrawal, the chmp had concerns and was of the provisional opinion that orathecin could not be approved for treatment of patients with advanced or metastatic pancretic cancer.
na podlagi pregleda podatkov in odgovorov podjetja na seznam vprašanj, ki jih je zastavil chmp, je imel odbor v času umika vloge zadržke in bil začasnega mnenja, da za zdravilo ni mogoče odobriti dovoljenja za zdravljenje bolnikov z napredovalim ali metastatskim rakom trebušne slinavke.

the studies looked at how long the patients survived after receiving orathecin, compared to those receiving the standard medicines used to treat pancreatic cancer, including 5-fluorouracil (5-fu) or gemcitabine.
v raziskavah so ugotavljali, kako dolgo so bolniki preživeli, če so prejemali zdravilo orathecin.